AC
$1.31
+0.04
(+3.15%)
As of Oct 5, 2026, 4:19 PM EDT · cached
Price history
Acurx Pharmaceuticals (ACXP) is trading up at $1.31 (+3.15%), as of the latest quote. It operates in the Health Care sector.
IPO: June 25, 2021 · $6.00 offering · NASDAQ · View IPO details →
Acurx Pharmaceuticals net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | — | — | — | — | −$14.1M | −$8.09M |
| Net income | −$4.60M | −$12.7M | −$12.1M | −$14.6M | −$14.1M | −$7.97M |
| EPS (diluted) | −$14.80 | −$29.80 | −$22.40 | −$23.00 | −$17.45 | −$5.32 |
| Balance sheet | ||||||
| Cash and equivalents | $3.18M | $13.0M | $9.11M | $7.47M | $3.71M | $7.56M |
| Total assets | $3.22M | $13.3M | $9.38M | $7.71M | $3.86M | $7.69M |
| Total liabilities | $522.4K | $843.9K | $2.06M | $3.04M | $3.24M | $2.42M |
| Shareholders' equity | $2.70M | $12.4M | $7.32M | $4.67M | $615.1K | $5.27M |
| Cash flow | ||||||
| Operating cash flow | −$3.35M | −$5.01M | −$7.54M | −$9.80M | −$10.4M | −$6.79M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$2.83M | −$2.79M | −$2.18M | −$2.27M | −$2.03M | −$1.62M | −$1.72M | −$2.31M |
| Net income | −$2.82M | −$2.78M | −$2.15M | −$2.25M | −$1.99M | −$1.58M | −$1.68M | −$2.25M |
| EPS (diluted) | −$3.45 | −$3.19 | −$2.15 | −$1.89 | −$1.23 | −$0.05 | −$0.62 | −$0.53 |
| Balance sheet | ||||||||
| Cash and equivalents | $5.76M | $3.71M | $4.64M | $6.06M | $5.91M | $7.56M | $9.25M | $10.7M |
| Total assets | — | $3.86M | — | — | $6.11M | $7.69M | $9.54M | $11.0M |
| Total liabilities | $3.32M | $3.24M | $2.49M | $2.59M | $2.47M | $2.42M | $2.53M | $2.83M |
| Shareholders' equity | $2.66M | $615.1K | $2.31M | $3.57M | $3.64M | $5.27M | $7.01M | $8.15M |
| Cash flow | ||||||||
| Operating cash flow | −$2.19M | −$2.25M | −$2.05M | −$1.67M | −$1.88M | −$1.18M | −$1.41M | −$1.71M |
From Acurx Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Acurx Pharmaceuticals
- Headquarters
- Staten Island, New York From SEC filings, Oct 2026
Recent News (1)
Other Health Care companies to compare with ACXP
- ACRS Aclaris Therapeutics Inc
- ACRV Acrivon Therapeutics
- ACTU Actuate Therapeutics Inc
- ACU Acme United Corp
- ADAG Adagene
- ADCT Adc Therapeutics SA
- ADMA Adma Biologics Inc
- ADPT Adaptive Biotechnologies Corp